Every 8-K that Avantor, Inc. (AVTR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTR filings page.
Avantor, Inc. (AVTR) filed an amended current report to update details about the previously announced transition and planned departure of Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products. Avantor, through its subsidiary VWR International, LLC, and Mr. Gourdier entered into a Transition Agreement on August 21, 2026, under which he will remain employed through October 14, 2026, when his employment will end. If he remains employed and complies with the Transition Agreement through that date, he will receive severance benefits materially consistent with the company’s Executive Severance and Change in Control Plan, as described in Avantor’s March 27, 2026 proxy statement.
Avantor, Inc. reported Q2 2026 net sales of $1,692.3 million, up 0.5% year over year, with organic net sales down 0.4%. Net income was $38.1 million, down from $64.7 million, and net income margin was 2.3%. Adjusted net income was $143.3 million and Adjusted EBITDA $254.3 million, for a 15.0% Adjusted EBITDA margin.
VWR Distribution & Services net sales were $1,240.5 million, up 2.7% reported and 1.7% organically, while Bioscience & Medtech Products net sales declined 5.1% to $451.8 million, with a 5.6% organic decrease. Adjusted Operating Income was $126.4 million for VWR and $117.6 million for Bioscience & Medtech, with margins of 10.2% and 26.0%, respectively.
Operating cash flow was $178.2 million and free cash flow $142.8 million, which the company used in part to repay $112.1 million of debt. Total debt was $3,715.4 million and cash and cash equivalents $306.8 million, resulting in Adjusted net leverage of 3.3x. Avantor raised its 2026 organic revenue growth guidance to a range of -0.5% to +0.5% and its Adjusted EPS guidance to $0.80–$0.83.
Avantor, Inc., through its wholly owned subsidiary Avantor Funding, Inc., entered into Amendment No. 15 to its Credit Agreement on July 14, 2026. Under this amendment, the subsidiary obtained a new tranche of senior secured Euro-denominated term loans totaling €374,208,296.62, designated as Incremental B-7 Euro Term Loans.
These loans bear interest at the floating EURIBO Rate + 2.00% per annum and replace certain existing senior secured euro term loans that carried a rate of EURIBO Rate + 2.50%, while maintaining the same final stated maturity of October 9, 2032. The Incremental B-7 Euro Term Loans are guaranteed by the same subsidiaries and secured by the same collateral as the existing credit facilities on a pari passu basis.
The amendment also introduces a 1.00% prepayment premium if, within six months of the effective date, the Borrower prepays, replaces or refinances these Incremental B-7 Euro Term Loans with broadly syndicated term B credit facilities that have a lower effective yield, excluding transactions linked to a change of control or certain transformative acquisitions.
Avantor, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 7, 2026. Stockholders elected nine directors to one-year terms expiring at the 2027 annual meeting, with each nominee receiving substantially more votes for than against.
Stockholders approved, on an advisory basis, the 2025 compensation of the company’s named executive officers and chose one year as the preferred frequency for future advisory votes on executive pay. Based on this, the board will hold say-on-pay votes annually until the next required frequency vote, expected at the 2032 annual meeting.
Stockholders also ratified the appointment of Deloitte & Touche LLP as Avantor’s independent registered public accounting firm for the year ending December 31, 2026.
Avantor reported mixed first-quarter 2026 results with weaker profitability but steady sales and reaffirmed guidance. Net sales were $1,581.4 million, flat with a year earlier, while foreign currency tailwinds meant organic net sales declined 4.1%.
Net income fell to $43.3 million from $64.5 million, and diluted GAAP EPS declined to $0.06 from $0.09. Adjusted net income was $114.0 million versus $155.2 million, with adjusted EPS down to $0.17 from $0.23 and adjusted EBITDA decreasing to $219.4 million, a 13.9% margin versus 17.0%.
Segment results showed lower adjusted operating income in both VWR Distribution & Services and Bioscience & Medtech Products. Operating cash flow was $58.7 million compared with $109.3 million, and free cash flow was $25.2 million versus $82.1 million. As of March 31, 2026, adjusted net leverage was 3.3x. The company reaffirmed its full-year 2026 financial guidance.
Avantor, Inc. announced a leadership transition in its Bioscience & Medtech Products segment. The company hired Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026, to lead growth, operational performance and the Revival Management Office.
The current Executive Vice President, Bioscience and Medtech Products, Benoit Gourdier, will move into a role supporting segment integration activities and is expected to depart the company no later than December 31, 2026. The changes focus on business transformation and integration across Avantor’s enterprise.
Avantor, Inc. announced a planned CFO transition and reaffirmed its fiscal 2026 guidance. Executive Vice President and CFO R. Brent Jones will leave the company on or before June 24, 2026, after providing 90 days’ notice under his employment agreement unless waived.
Upon his departure, Senior Vice President and Chief Accounting Officer Steve Eck will serve as interim CFO while continuing as principal accounting officer as the company conducts a search for a permanent CFO. To reflect his expanded responsibilities, Eck will receive an additional $45,000 per month for each month he serves as interim CFO and a one-time $250,000 restricted stock unit award vesting ratably over three years.
The company highlighted Eck’s extensive finance and accounting background and stated that its previously issued fiscal 2026 financial guidance from its fourth quarter 2025 earnings call remains unchanged.
Avantor, Inc. filed an amended current report to update board responsibilities for a recently elected director. The company had previously reported the election of Simon Dingemans to its Board of Directors effective January 2, 2026, but at that time had not yet determined his committee assignments.
This amendment specifies that, effective February 19, 2026, Mr. Dingemans was appointed to serve on Avantor’s Audit & Finance Committee. No financial results or major transactions are discussed in this update, which focuses solely on this corporate governance detail.
Avantor, Inc. filed an amended report to update the board responsibilities of director Sanjeev Mehra. When he was elected to the board effective December 4, 2025, his committee assignments had not yet been decided. The amendment discloses that, effective February 19, 2026, Mehra joined both the Compensation & Human Resources Committee and the Audit & Finance Committee. The filing also includes an exhibit providing the cover page formatted in Inline XBRL.
Avantor reported weaker results for the fourth quarter and full year 2025 and announced a major segment realignment. Fourth-quarter net sales were $1.66 billion, down 1.4% year over year, with organic sales down 4.1%. Net income fell sharply to $52 million, while adjusted EBITDA was $252 million with a 15.2% margin and adjusted EPS of $0.22.
For full year 2025, net sales were $6.55 billion, down 3.4% (2.8% organic decline). The company posted a net loss of $530 million, compared with net income of $712 million in 2024, largely reflecting a $785 million goodwill impairment. Adjusted EBITDA was $1.07 billion with a 16.3% margin and adjusted EPS of $0.90. Operating cash flow remained solid at $624 million, generating free cash flow of $496 million and adjusted net leverage of 3.2x.
Laboratory Solutions full‑year net sales declined 4.6% to $4.40 billion and Bioscience Production declined 1.0% to $2.15 billion, with margins compressing in both. Avantor is executing a “Revival” program, including relaunching the VWR brand and supply chain and e‑commerce improvements, and will realign into two new segments—VWR Distribution & Services and Bioscience & Medtech Products—starting with the first quarter of 2026.
Avantor, Inc. disclosed that its Board of Directors has elected Simon Dingemans as a director, effective January 2, 2026. His initial term will run until the company’s 2026 Annual Meeting of Stockholders and he will fill the vacancy created by Jonathan Peacock’s previously announced resignation, which becomes effective December 31, 2025.
Dingemans brings extensive financial and deal-making experience, having served as Chief Financial Officer of GSK plc from 2011 to 2019 and previously holding senior roles at The Carlyle Group, Goldman Sachs and SG Warburg. He currently sits on the boards of Vodafone Group Plc, WPP plc and Genomics Limited. The Board determined that he meets the independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
As a non-employee director, he will receive Avantor’s standard compensation: an annual cash retainer of $95,000, paid quarterly, and a grant of restricted stock units with a grant date fair value of $210,000, prorated for his service before the 2026 annual meeting. These restricted stock units are scheduled to vest in full on May 6, 2026, subject to his continued service. Avantor also noted that it issued a press release about his election on December 18, 2025, furnished as an exhibit.
Avantor, Inc. announced that its Board of Directors has elected Sanjeev Mehra as a director, with an initial term running until the company’s 2026 Annual Meeting of Stockholders. The Board determined he meets the independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
Mehra, age 66, is Co‑Founder and Managing Partner of Periphas Capital and previously held senior roles at Goldman Sachs from 1986 to 2017, including Partner and Vice Chairman of the Global Private Equity business. He currently serves on the board of OPENLANE, Inc.
As a non‑employee director, he will receive standard compensation: an annual cash retainer of $95,000, prorated for 2025, and a grant of restricted stock units with a grant date fair value of $210,000, also prorated, vesting in full one year from grant subject to continued service. Avantor also issued a press release about his election, furnished as an exhibit.
Avantor (AVTR) appointed Mary Blenn as Executive Vice President and Chief Operating Officer. Her compensation includes a $500,000 annual base salary and an annual cash bonus target of 75% of base salary, pro‑rated for 2025.
The Offer Letter provides an initial equity grant with a target grant date fair value of $5,000,000: $400,000 at start in 2025 (50% RSUs, 50% stock options, vesting ratably over two years) and the remainder in February 2026 (25% RSUs, 25% options, 50% PSUs; RSUs/options vest ratably over three years and PSUs cliff vest based on 2026–2029 performance). Beginning in 2028, she will be eligible for a long‑term incentive target of $2,300,000.
The filing also corrects the CEO’s education disclosure: Emmanuel Ligner holds a Licence and Maitrise in Commerce from Université de Savoie. In addition, effective November 6, 2025, director Gregory Lucier was appointed to the Compensation & Human Resources Committee and the Nominating & Governance Committee.
Avantor, Inc. filed a current report to note that it released a press release with its financial results for the quarter ended September 30, 2025. The press release was issued on October 29, 2025 and is attached as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed filed for liability purposes under the Securities Exchange Act.
Avantor, Inc. amended its senior secured credit facilities to bolster liquidity and extend maturities. The Amended Credit Agreement adds replacement and incremental revolving credit commitments totaling $1.4 billion, a new €400 million Incremental Euro Term A Loan, and a new €550 million Incremental B‑6 Euro Term Loan. The revolving facility and Term A mature on October 9, 2030, and the Term B on October 9, 2032.
Proceeds will repay or refinance existing secured debt, including the accounts receivable securitization and remaining first‑lien notes, cover related fees, and provide additional liquidity. On the Termination Date, approximately $208 million outstanding under the up to $300 million A/R Facility was repaid in full and the facility was terminated. The Borrower redeemed €400 million of 2.625% Senior First Lien Notes on August 29, 2025 and the remaining €250 million on October 10, 2025.
The Term B loan bears interest at benchmark plus 2.50%. Obligations are guaranteed by substantially all wholly owned domestic subsidiaries (excluding the Company) and are secured by substantially all assets, subject to customary exceptions, with customary covenants and events of default.
Avantor, Inc. announced that Jonathan Peacock will step down as chairman, director, and member of the Nominating and Governance Committee on December 31, 2025. The company stated his decision was not due to any disagreement regarding its operations, policies, or practices.
Current director Gregory L. Summe will serve as the next chairman effective January 1, 2026. The transition details were also provided in a press release furnished under Regulation FD.
Avantor, Inc. reported that its Board of Directors elected Gregory Lucier as a director, effective October 3, 2025, with an initial term running until the 2026 Annual Meeting of Stockholders. The Board determined he meets New York Stock Exchange and Exchange Act independence standards.
Lucier is Executive Chairman and CEO of Corza Medical and previously led NuVasive and Life Technologies, with earlier leadership roles at General Electric. He will receive Avantor’s standard non-employee director compensation, including a prorated $95,000 annual cash retainer and restricted stock units with a grant date fair value of $210,000, vesting in full one year after grant. Avantor also issued a press release announcing his election, furnished as Exhibit 99.
Avantor, Inc. elected Emmanuel Ligner as a director, with an initial term commencing on August 18, 2025 and expiring at the company’s 2026 Annual Meeting of Stockholders. The Board selected Mr. Ligner to fill a vacant seat and the company disclosed that he will receive no additional compensation for his service on the Board. The company noted that Mr. Ligner will begin serving as President and Chief Executive Officer as previously reported.
The filing references prior disclosure of his employment terms and states that an employment contract dated July 15, 2025 between VWR International Ltd., a subsidiary, and Mr. Ligner will be filed with the quarterly report for the period ending September 30, 2025. The company also reported there are no arrangements or understandings with other persons about his selection and that he has no direct or indirect material interest in transactions requiring disclosure.